Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Finished Goods (2021 - 2024)

Historic Finished Goods for Apellis Pharmaceuticals (APLS) over the last 4 years, with Q1 2024 value amounting to $13.0 million.

  • Apellis Pharmaceuticals' Finished Goods rose 32522.02% to $13.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $13.0 million, marking a year-over-year increase of 32522.02%. This contributed to the annual value of $30.7 million for FY2023, which is 163918.46% up from last year.
  • According to the latest figures from Q1 2024, Apellis Pharmaceuticals' Finished Goods is $13.0 million, which was up 32522.02% from $30.7 million recorded in Q4 2023.
  • Apellis Pharmaceuticals' Finished Goods' 5-year high stood at $30.7 million during Q4 2023, with a 5-year trough of $479000.0 in Q4 2021.
  • In the last 4 years, Apellis Pharmaceuticals' Finished Goods had a median value of $2.4 million in 2022 and averaged $9.4 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Finished Goods skyrocketed by 26868.48% in 2022, and later surged by 290964.39% in 2023.
  • Apellis Pharmaceuticals' Finished Goods (Quarter) stood at $479000.0 in 2021, then soared by 268.68% to $1.8 million in 2022, then surged by 1639.18% to $30.7 million in 2023, then tumbled by 57.57% to $13.0 million in 2024.
  • Its last three reported values are $13.0 million in Q1 2024, $30.7 million for Q4 2023, and $20.3 million during Q3 2023.